New Releases | GenomeWeb

New Releases


Exiqon this week announced it was offering BRAF mutation analysis through its CLIA laboratory in California.

UK-based DxS previously announced it was offering its TheraScreen KRAS Test and BRAF test in the US through Exiqon.

"BRAF testing is important because it can identify the subset of colorectal cancer patients who do not have a mutated KRAS gene yet still do not respond to anti-EGFR therapy," Exiqon said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.